Effects of thyrotropin suppression on lumbar bone mineral density in postmenopausal women with differentiated thyroid carcinoma

References

• KungAWYeungSSPrevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitoninJ Clin Endocrinol Metab1996813123212368772604
   PubMed Web of Science ®Google Scholar
• GreenspanSLGreenspanFSResnickNMBlockJEFriedlanderALGenantHKSkeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapyAm J Med19919115141858829
   PubMed Web of Science ®Google Scholar
• Chinese Society of EndocrinologyDiagnosis and treatment guideline for thyroid nodules and differentiated cancerCancer Clin China20121712491272 Chinese
   Google Scholar
• HaugenBRAlexanderEKBibleKC2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid2016261113326462967
   PubMed Web of Science ®Google Scholar
• BiondiBCooperDSBenefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancerThyroid201020213514620151821
   PubMed Web of Science ®Google Scholar
• FranklynJAMaisonneuvePSheppardMCBetteridgeJBoylePMortality after the treatment of hyperthyroidism with radioactive iodineN Engl J Med1998338117127189494147
   PubMed Web of Science ®Google Scholar
• VestergaardPRejnmarkLWeekeJMosekildeLFracture risk in patients treated for hyperthyroidismThyroid200010434134810807063
   PubMed Web of Science ®Google Scholar
• UzzanBCamposJCucheratMNonyPBoisselJPPerretGYEffects on bone mass of long term treatment with thyroid hormones: a meta-analysisJ Clin Endocrinol Metab19968112427842898954028
   PubMed Web of Science ®Google Scholar
• SugitaniIFujimotoYEffect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled studySurgery201115061250125722136848
   PubMed Web of Science ®Google Scholar
• TournisSAntoniouJDLiakouCGVolumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppressionClin Endocrinol2015822197204
   Web of Science ®Google Scholar
• KimMKYunKJKimMHThe effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinomaBone20157110110525445448
   PubMed Web of Science ®Google Scholar
• FlynnRWBonellieSRJungRTMacDonaldTMMorrisADLeeseGPSerum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapyJ Clin Endocrinol Metab201095118619319906785
   PubMed Web of Science ®Google Scholar
• MorrisMSThe association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American womenBone20074041128113417236836
   PubMed Web of Science ®Google Scholar
• KimCWHongSOhSHChange of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid CarcinomaJ Bone Metab201522313514126389089
   PubMedGoogle Scholar
• LeeMYParkJHBaeKSBone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancerAnn Surg Treat Res2014862556024761409
   PubMed Web of Science ®Google Scholar
• ReverterJLHolgadoSAlonsoNSalinasIGranadaMLSanmartíALack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinomaEndocr Relat Cancer200512497398116322336
   PubMed Web of Science ®Google Scholar
• HeijckmannACHuijbertsMSGeusensPde VriesJMenheerePPWolffenbuttelBHHip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinomaEur J Endocrinol20051531232915994742
   PubMed Web of Science ®Google Scholar
• RickenRBermpohlFSchlattmannPLong-term treatment with supraphysiological doses of thyroid hormone in affective disorders – effects on bone mineral densityJ Affect Disord20121361–2e89e9421757236
   PubMed Web of Science ®Google Scholar
• MurphyEWilliamsGRThe thyroid and the skeletonClin Endocrinol2004613285298
   PubMed Web of Science ®Google Scholar
• ChinKYIma-NirwanaSMohamedINAminuddinAJohariMHNgahWZThyroid-stimulating hormone is significantly associated with bone health status in menInt J Med Sci201310785786323781131
   PubMed Web of Science ®Google Scholar
• MoserESikjaerTMosekildeLRejnmarkLBone Indices in Thyroidectomized Patients on Long-Term Substitution Therapy with Levothyroxine Assessed by DXA and HR-pQCTJ Thyroid Res2015201579687179687926246934
   PubMedGoogle Scholar
• SheuYZmudaJMBoudreauRMBone strength measured by peripheral quantitative computed tomography and the risk of nonvertebral fractures: the osteoporotic fractures in men (MrOS) studyJ Bone Miner Res2011261637120593412
   PubMed Web of Science ®Google Scholar
• El Hadidy elHMGhonaimMEl GawadSSHEl AttaMAImpact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in menBMC Endocr Disord2011111521819612
   PubMed Web of Science ®Google Scholar
• KarnerIHrgovićZSijanovićSBone mineral density changes and bone turnover in thyroid carcinoma patients treated with supra-physiologic doses of thyroxineEur J Med Res2005101148048816354602
   PubMed Web of Science ®Google Scholar
• QuanMLPasiekaJLRorstadOBone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literatureJ Surg Oncol2002791627011754378
   PubMed Web of Science ®Google Scholar
• de MeloTGda AssumpçãoLVSantosAOZantut-WittmannDELow BMI and low TSH value as risk factors related to lower bone mineral density in postmenopausal women under levothyroxine therapy for differentiated thyroid carcinomaThyroid Res20158726097507
   PubMedGoogle Scholar
• RosenHNMosesACGarberJRandomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronateJ Clin Endocrinol Metab1998837232423309661603
   PubMed Web of Science ®Google Scholar
• SunLDaviesTFBlairHCAbeEZaidiMTSH and bone lossAnn N Y Acad Sci2006106830931816831931
   PubMed Web of Science ®Google Scholar
• AbeEMariansRCYuWTSH is a negative regulator of skeletal remodelingCell2003115215116214567913
   PubMed Web of Science ®Google Scholar
• BlumMRBauerDCColletTHSubclinical thyroid dysfunction and fracture risk: a meta-analysisJAMA2015313202055206526010634
   PubMed Web of Science ®Google Scholar
• OngphiphadhanakulBAlexSBravermanLEBaranDTExcessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitoninJ Bone Miner Res1992710122712311456090
   PubMed Web of Science ®Google Scholar
• HwangboYKimJHKimSWHigh-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal womenOsteoporos Int201627245746226252978
   PubMed Web of Science ®Google Scholar
• MoonJHKimKMOhTJThe Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid CarcinomaJ Clin Endocrinol Metab20171021788527754806
   PubMed Web of Science ®Google Scholar